Rchr
J-GLOBAL ID:200901066555884752   Update date: Feb. 01, 2024

Katsumoto Takuo

カツモト タクオ | Katsumoto Takuo
Affiliation and department:
Research field  (4): Tumor biology ,  Hematology and oncology ,  Immunology ,  Molecular biology
Research keywords  (3): 造血幹細胞 ,  Epigenetics ,  Leukemia
Research theme for competitive and other funds  (6):
  • 2011 - 2013 MOZ/MLL融合遺伝子による急性骨髄性白血病発症機構の解明
  • 2010 - 2012 Development of the novel AML treatments by targeting leukemia stem cells
  • 2009 - 2011 造血幹細胞の自己複製における白血病関連因子MOZとMORFの機能の解明
  • 2007 - 2009 成人難治性白血病の分子生物学的特徴に基づく治療法に関する研究
  • 2007 - 2009 Study for regulatory mechanism of normal and leukemic stem cells through transcription factors
Show all
Papers (30):
  • Ayuna Hattori, Emi Takamatsu-Ichihara, Yoshiki Yamamoto, Shuhei Fujita, Kazutsune Yamagata, Takuo Katsumoto, Yukino Machida, Haruka Shinohara, Ryo Murakami, Issay Kitabayashi. Genetic and chemical targeting of the ATPase complex TIP48 and 49 impairs acute myeloid leukemia. Leukemia. 2023
  • Jumpei Ito, Kazutsune Yamagata, Haruka Shinohara, Yutaka Shima, Takuo Katsumoto, Yukiko Aikawa, Issay Kitabayashi. Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1. International Journal of Hematology. 2022. 117. 1. 78-89
  • Takuo Katsumoto, Yoko Ogawara, Kazutsune Yamagata, Yukiko Aikawa, Ryo Goitsuka, Takuro Nakamura, Issay Kitabayashi. MOZ is critical for the development of MOZ/MLL-fusion-induced leukemia through regulation of Hoxa9/Meis1 expression. Blood Advances. 2022. 6. 19. 5527-5537
  • 北林 一生, 相川 祐規子, 山形 和恒, 勝本 拓夫, 島 豊, 横山 明彦, 町田 雪乃, 篠原 悠, 小川原 陽子, 藤田 修平, et al. ドライバー変異と必須因子を標的とした分子標的治療法の開発を目指して. 日本癌学会総会記事. 2021. 80回. [MVA-4]
  • Yuki Kagiyama, Shuhei Fujita, Yutaka Shima, Kazutsune Yamagata, Takuo Katsumoto, Makoto Nakagawa, Daisuke Honma, Nobuaki Adachi, Kazushi Araki, Ayako Kato, et al. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib. Cancer science. 2021. 112. 6. 2314-2324
more...
MISC (14):
  • Issay Kitabayashi, Yukiko Aikawa, Kazutsune Yamagata, Takuo Katsumoto, Yutaka Shima, Akihiko Yokoyama, Yukino Machida, Haruka Shinohara, Yoko Ogawara, Shuhei Fujita, et al. Targeting driver mutations and critical factors in hematological and solid cancers. CANCER SCIENCE. 2022. 113. 1256-1256
  • 北林一生, 相川祐規子, 山形和恒, 勝本拓夫, 島豊, 横山明彦, 町田雪乃, 篠原悠, 小川原陽子, 藤田修平, et al. ドライバー変異と必須因子を標的とした分子標的治療法の開発を目指して. 日本癌学会学術総会抄録集(Web). 2021. 80th
  • Kazutsune Yamagata, Mariko Saito, Mai Suzuki, Takuo Katsumoto, Honami Ogoh, Toshio Watanabe, Issay Kitabayashi. AF10 links histone chaperones Supt6h and FACT complex to MLL-fusion leukemia. CANCER SCIENCE. 2018. 109. 1111-1111
  • Takuo Katsumoto, Kazutsune Yamagata, Yoko Ogawara, Takuro Nakamura, Issay Kitabayashi. Essential Role of Endogenous MOZ in Aberrant HoxA9 and Meis1 Expressions Induced By MOZ Fusion Gene. BLOOD. 2014. 124. 21
  • Yoko Ogawara, Takuo Katsumoto, Yukiko Aikawa, Yuki Kagiyama, Issay Kitabayashi. NPMC COOPERATES WITH MUTANT IDH2 TO INDUCE ACUTE MYELOID LEUKEMIA. EXPERIMENTAL HEMATOLOGY. 2013. 41. 8. S55-S55
more...
Education (3):
  • 2000 - 2004 Chiba University Graduate School of Medicine Biomedical Science
  • 1998 - 2000 University of Tsukuba
  • 1994 - 1998 Ibaraki University
Professional career (1):
  • 医学博士 (千葉大学)
Work history (6):
  • 2023/04 - 現在 Japan Agency for Medical Research and Development
  • 2015/04 - 2023/03 国立研究開発法人国立がん研究センター 研究所・造血器腫瘍研究分野 研究員
  • 2010/04 - 2015/03 Division of Hemarological Malignancy, National Cancer Center Research Institute
  • 2007/04 - 2010/03 Division of Molecular Oncology, National Cancer Center Research Institute
  • 2004/04 - 2007/03 がん研究振興財団リサーチ・レジデント
Show all
Association Membership(s) (1):
日本癌学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page